[go: up one dir, main page]

AR032641A1 - Agonista de subtipo de receptor 5-ht 1a. - Google Patents

Agonista de subtipo de receptor 5-ht 1a.

Info

Publication number
AR032641A1
AR032641A1 ARP020100118A ARP020100118A AR032641A1 AR 032641 A1 AR032641 A1 AR 032641A1 AR P020100118 A ARP020100118 A AR P020100118A AR P020100118 A ARP020100118 A AR P020100118A AR 032641 A1 AR032641 A1 AR 032641A1
Authority
AR
Argentina
Prior art keywords
subtipe
agonist
receiver
carbon
bond
Prior art date
Application number
ARP020100118A
Other languages
English (en)
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25087808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR032641(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR032641A1 publication Critical patent/AR032641A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere a un método de tratar un paciente que sufre de un desorden del sistema nervioso central asociado con subtipo de receptor 5 û HT1A, que comprende como un ingrediente activo un derivado de carboestirilo o una sal del mismo representado por la formula (1) en donde el enlace carbono-carbono entre posiciones 3 ûy 4- en el esqueleto de carboestirilo es un enlace simple o doble.
ARP020100118A 2001-01-29 2002-01-15 Agonista de subtipo de receptor 5-ht 1a. AR032641A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77021001A 2001-01-29 2001-01-29

Publications (1)

Publication Number Publication Date
AR032641A1 true AR032641A1 (es) 2003-11-19

Family

ID=25087808

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP020100118A AR032641A1 (es) 2001-01-29 2002-01-15 Agonista de subtipo de receptor 5-ht 1a.
ARP100104973A AR079761A2 (es) 2001-01-29 2010-12-28 Agonista de subtipo de receptor 5-ht1a
ARP110101189A AR080849A2 (es) 2001-01-29 2011-04-08 Uso de una composicion farmaceutica de un compuesto de carboestirilo
ARP150100766A AR099754A2 (es) 2001-01-29 2015-03-13 Composición farmacéutica agonista de subtipo de receptor 5-ht₁a

Family Applications After (3)

Application Number Title Priority Date Filing Date
ARP100104973A AR079761A2 (es) 2001-01-29 2010-12-28 Agonista de subtipo de receptor 5-ht1a
ARP110101189A AR080849A2 (es) 2001-01-29 2011-04-08 Uso de una composicion farmaceutica de un compuesto de carboestirilo
ARP150100766A AR099754A2 (es) 2001-01-29 2015-03-13 Composición farmacéutica agonista de subtipo de receptor 5-ht₁a

Country Status (19)

Country Link
EP (3) EP1621198B1 (es)
JP (4) JP4178032B2 (es)
KR (5) KR100601073B1 (es)
CN (3) CN1239154C (es)
AR (4) AR032641A1 (es)
AT (3) ATE322894T1 (es)
AU (4) AU2002226752C1 (es)
BR (1) BR0206237A (es)
CA (2) CA2429496C (es)
CY (3) CY1105631T1 (es)
DE (3) DE60210581T2 (es)
DK (3) DK1621198T3 (es)
ES (3) ES2261652T3 (es)
MX (2) MX344556B (es)
MY (1) MY129355A (es)
PH (1) PH12014500937A1 (es)
PT (3) PT1621198E (es)
TW (2) TWI331919B (es)
WO (1) WO2002060423A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
MXPA05000294A (es) * 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
EP1723957A3 (en) 2002-12-27 2013-01-23 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
UA92453C2 (ru) 2003-05-23 2010-11-10 Оцука Фармасьютикел Ко., Лтд. Производные карбостирила и стабилизаторы настроения для лечения расстройств настроения
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
WO2006090273A2 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
PL1912650T3 (pl) * 2005-08-03 2018-01-31 Sprout Pharmaceuticals Inc Zastosowanie flibanseryny w leczeniu otyłości
TW200848041A (en) * 2007-03-30 2008-12-16 Otsuka Pharma Co Ltd A medicament for treating schizophrenia comprising cilostazol
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
JP2009286740A (ja) * 2008-05-30 2009-12-10 Otsuka Pharmaceut Co Ltd アリピプラゾールを含有する逆耐性抑制剤
EP2338873A1 (en) 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
TW201343201A (zh) 2012-03-06 2013-11-01 Otsuka Pharma Co Ltd 持續釋放型口服固體製劑
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
DE3721799C2 (de) 1986-07-01 1993-12-23 Mitsubishi Electric Corp Integrierte Redox-Bauelementschaltung und Verfahren zum Herstellen
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
EP0586525B1 (en) * 1991-05-20 1997-04-16 PHARMACIA & UPJOHN COMPANY Carboxamido-(1,2n)-carbocyclic-2-aminotetralin derivatives
US5532240A (en) * 1991-12-26 1996-07-02 Yoshitomi Pharmaceutical Industries, Ltd. Condensed thiophene compound and pharmaceutical use thereof
AU5446894A (en) * 1992-10-23 1994-05-24 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
DK148292D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
JP2959615B2 (ja) * 1993-06-24 1999-10-06 吉富製薬株式会社 縮合型チオフェン化合物およびその医薬用途
JPH09291034A (ja) * 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US5688950A (en) * 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
NZ508303A (en) * 1996-05-07 2001-07-27 Pfizer Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (ziprasidone) useful as a dopamine D2 antagonist
JP4012994B2 (ja) * 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
AU4091697A (en) * 1996-08-27 1998-03-19 American Home Products Corporation 4-aminoethoxy indoles as dopamin d2 agonists and as 5ht1a ligands
JP2002501920A (ja) * 1998-02-03 2002-01-22 アメリカン・ホーム・プロダクツ・コーポレイション セロトニン−１ａ受容体作動薬としてのオキサゾール誘導体
CN1297439A (zh) * 1998-04-13 2001-05-30 美国家用产品公司 4－(氨基)－(乙氨基)－羟吲哚多巴胺自身受体激动剂
JPH11335286A (ja) * 1998-05-25 1999-12-07 Mitsui Chem Inc ドーパミン拮抗薬の効果増強剤
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
JP4205577B2 (ja) * 2001-06-19 2009-01-07 ミュラー，ノルベルト 精神分裂病、妄想障害、情動障害、自閉症またはチック障害の治療のためのｃｏｘ−２阻害薬の使用
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma

Also Published As

Publication number Publication date
WO2002060423A3 (en) 2003-04-10
AU2007201701A1 (en) 2007-05-10
WO2002060423A2 (en) 2002-08-08
ATE362763T1 (de) 2007-06-15
BR0206237A (pt) 2003-12-23
AU2002226752B2 (en) 2005-03-17
JP4896831B2 (ja) 2012-03-14
KR100601073B1 (ko) 2006-07-19
PT1712225E (pt) 2011-04-18
CA2429496A1 (en) 2002-08-08
KR100825705B1 (ko) 2008-04-29
AU2007201701B2 (en) 2010-06-17
KR100763288B1 (ko) 2007-10-04
PH12014500937A1 (en) 2015-09-21
HK1061805A1 (en) 2004-10-08
AU2009233591A1 (en) 2009-11-19
DE60210581D1 (en) 2006-05-24
HK1091403A1 (zh) 2007-01-19
DE60210581T2 (de) 2007-04-05
MXPA03006603A (es) 2004-02-12
MX344556B (es) 2016-12-20
ATE504293T1 (de) 2011-04-15
DK1621198T3 (da) 2007-09-24
DE60239711D1 (de) 2011-05-19
JP4178032B2 (ja) 2008-11-12
KR20050107822A (ko) 2005-11-15
EP1712225A1 (en) 2006-10-18
KR20030065570A (ko) 2003-08-06
ES2261652T3 (es) 2006-11-16
CN1879624A (zh) 2006-12-20
JP2004517937A (ja) 2004-06-17
CY1105631T1 (el) 2010-12-22
CY1111392T1 (el) 2015-08-05
ES2286755T3 (es) 2007-12-01
JP5683010B2 (ja) 2015-03-11
MY129355A (en) 2007-03-30
KR20060028485A (ko) 2006-03-29
PT1355639E (pt) 2006-06-30
AU2005201772C1 (en) 2010-06-03
AU2005201772A1 (en) 2005-05-19
EP1621198A2 (en) 2006-02-01
EP1712225B1 (en) 2011-04-06
EP1621198B1 (en) 2007-05-23
EP1355639B1 (en) 2006-04-12
KR20070065425A (ko) 2007-06-22
DK1712225T3 (da) 2011-06-20
CA2429496C (en) 2010-10-19
KR100713607B1 (ko) 2007-05-02
JP2011184460A (ja) 2011-09-22
AU2005201772B2 (en) 2007-05-17
JP2011225587A (ja) 2011-11-10
CN1813745A (zh) 2006-08-09
EP1355639A2 (en) 2003-10-29
CN100450485C (zh) 2009-01-14
PT1621198E (pt) 2007-06-08
DE60220325T2 (de) 2008-01-17
DK1355639T3 (da) 2006-08-14
DE60220325D1 (de) 2007-07-05
CN1239154C (zh) 2006-02-01
TW200522960A (en) 2005-07-16
CN1484524A (zh) 2004-03-24
JP2007297405A (ja) 2007-11-15
AU2002226752C1 (en) 2010-02-18
AR080849A2 (es) 2012-05-09
CY1108031T1 (el) 2013-09-04
CA2700314A1 (en) 2002-08-08
AR079761A2 (es) 2012-02-15
AU2009233591B2 (en) 2011-10-20
AR099754A2 (es) 2016-08-17
EP1621198A3 (en) 2006-04-12
KR100653591B1 (ko) 2006-12-05
ES2363366T3 (es) 2011-08-02
CA2700314C (en) 2012-04-24
TWI331919B (en) 2010-10-21
KR20060085260A (ko) 2006-07-26
TWI302832B (en) 2008-11-11
ATE322894T1 (de) 2006-04-15

Similar Documents

Publication Publication Date Title
AR032641A1 (es) Agonista de subtipo de receptor 5-ht 1a.
ATE459357T1 (de) Kombinationen zur behandlung von multiplem myelom
GT200000019A (es) Inhibidores de la recaptacion de monoaminas para el tratamiento de trastornos del snc.
EP2178870A4 (en) INDOL AND INDAZONE COMPOUNDS AS AN INHIBITORS OF CELL NECROSIS
ATE466014T1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
ATE482209T1 (de) Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MY144483A (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
DE60229530D1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
CR20120190A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
NO20082011L (no) Acylerte spiropiperidinderivater som melanocortin-4-reseptormodulatorer
BRPI0414792A (pt) derivados de ácido 4-(1h-indol-3-il-metilidenoaminóxi-propóxi)-benzóico e compostos relacionados como inibidores de pai-1 para o tratamento de enfraquecimento do sistema fibrinolìtico e de trombose
MXPA05002942A (es) Forma de dosificacion oral de liberacion modificada.
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
MX2010003948A (es) N-fenil-birrolidin ureas sustituidas y uso terapeutico de las mismas.
NO20014529D0 (no) Tetrahydropyranderivater og deres anvendelse som terapautiske midler
EA200700909A1 (ru) Азаиндолкарбоксамиды
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
TW200611695A (en) Pyrrolopyridine derivatives
PA8663501A1 (es) Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilcondensados
NO20054494L (no) Peptidvektorer
GT200400041A (es) Derivados azabiciclicos de piridiloximetilo y bencisoxazol
WO2001091796A8 (en) Methods, compounds and compositions for treating gout
GT199700096A (es) Ligandos espirociclos de un subtipo de receptor de la dopamina.
UA74430C2 (uk) Похідні фенілгетероциклічних етерів як інгібітори зворотного захоплення серотоніну

Legal Events

Date Code Title Description
FC Refusal